Adam graduated from Augsburg University in 2018 with a B.S. in chemistry and minors in mathematics and biology. As an undergraduate, Adam worked with Dr. Michael Wentzel at Augsburg University to develop improved synthetic methods for amine alkylation using palladium catalysts. In the Summer of 2018, Adam engaged in a pharmaceutical chemistry research program at the University of Kansas where he worked under Dr. Cory Berkland to develop antigen-specific immunotherapies to treat autoimmune disorders. Adam joined the Hergenrother lab in the Fall of 2019. He is now working to synthesize a library of complex molecules with covalent warheads in order to discover new covalent inhibitors for drug targets.